Leroux, StéphanieDivision of Neonatology, Department of Child and Adolescent Medicine, CHU de Rennes, Rennes, France
Thomson, Alison HPharmacy Department, Glasgow Royal Infirmary, Glasgow, UK
Allegaert, KarelIntensive Care, Erasmus MC – Sophia Children's Hospital, Rotterdam, The Netherlands
Capparelli, Edmund VPediatric Pharmacology and Drug Discovery, University of California, San Diego, CA, USA
Biran, ValérieNeonatal Intensive Care Unit, Hôpital Robert Debré, Paris, France
Simon, NicolasAix Marseille University, INSERM, IRD, SESSTIM, Marseille, France
Meibohm, BerndDepartment of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USA
Lo, Yoke-LinSchool of Pharmacy, International Medical University, Kuala Lumpur, Malaysia
Marques, RemediosDepartment of Pharmacy Services, La Fe Hospital, Valencia, Spain
Peris, José-EstebanDepartment of Pharmacy and Pharmaceutical Technology, University of Valencia, Valencia, Spain
Lutsar, IrjaInstitute of Medical Microbiology, University of Tartu, Tartu, Estonia
Saito, JumpeiDepartment of Pharmacy, National Children’s Hospital National Center for Child Health and Development, Tokyo, Japan
Nakamura, HidefumiDepartment of Development Strategy, Center for Clinical Research and Development, National Center for Child Health and Development, Tokyo, Japan
van den Anker, Johannes NDepartment of Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland
Sharland, MikePaediatric Infectious Disease Unit, St George’s Hospital, London, UK
Zhao, Wei
ORCID
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China
EnglishAbstract Objectives In the absence of consensus, the present meta-analysis was performed to determine an optimal dosing regimen of vancomycin for neonates.
Methods A ‘meta-model’ with 4894 concentrations from 1631 neonates was built using NONMEM, and Monte Carlo simulations were performed to design an optimal intermittent infusion, aiming to reach a target AUC0–24 of 400 mg·h/L at steady-state in at least 80% of neonates.
Results A two-compartment model best fitted the data. Current weight, postmenstrual age (PMA) and serum creatinine were the significant covariates for CL. After model validation, simulations showed that a loading dose (25 mg/kg) and a maintenance dose (15 mg/kg q12h if <35 weeks PMA and 15 mg/kg q8h if ≥35 weeks PMA) achieved the AUC0–24 target earlier than a standard ‘Blue Book’ dosage regimen in >89% of the treated patients.
Conclusions The results of a population meta-analysis of vancomycin data have been used to develop a new dosing regimen for neonatal use and to assist in the design of the model-based, multinational European trial, NeoVanc.